Regulatory T (Treg) cells maintain immune tolerance through the master transcription factor forkhead box P3 (FOXP3), which is crucial for Treg cell function and homeostasis. We identified an IPEX (immune dysregulation polyendocrinopathy enteropathy X-linked) syndrome patient with a FOXP3 mutation in the domain swap interface of the protein. Recapitulation of this Foxp3 variant in mice led to the development of an autoimmune syndrome consistent with an unrestrained T helper type 2 (Th2) immune response. Genomic analysis of Treg cells by RNA-sequencing, Foxp3 chromatin immunoprecipitation followed by high-throughput DNA sequencing (ChIP-sequencing), and H3K27ac-HiChIP revealed a specific de-repression of the Th2 transcriptional program leading to the generation of Th2-like Treg cells that were unable to suppress extrinsic Th2 cells. Th2-like Treg cells showed increased intra-chromosomal interactions in the Th2 locus, leading to type 2 cytokine production. These findings identify a direct role for Foxp3 in suppressing Th2-like Treg cells and implicate additional pathways that could be targeted to restrain Th2 trans-differentiated Treg cells.
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In Brief
Naturally occurring FOXP3 mutations provide unique opportunities to leverage clinical observations to increase our understanding of fundamental Treg cell biology. Van Gool et al. identify a mutation in the domain-swap interface of FOXP3 in IPEX patients and demonstrate a direct role for the mutant FOXP3 in reprogramming Treg cells to acquire a Th2-like phenotype, leading to Th2-mediated autoimmunity.
SUMMARY
Regulatory T (Treg) cells maintain immune tolerance through the master transcription factor forkhead box P3 (FOXP3), which is crucial for Treg cell function and homeostasis. We identified an IPEX (immune dysregulation polyendocrinopathy enteropathy X-linked) syndrome patient with a FOXP3 mutation in the domain swap interface of the protein. Recapitulation of this Foxp3 variant in mice led to the development of an autoimmune syndrome consistent with an unrestrained T helper type 2 (Th2) immune response. Genomic analysis of Treg cells by RNA-sequencing, Foxp3 chromatin immunoprecipitation followed by high-throughput DNA sequencing (ChIP-sequencing), and H3K27ac-HiChIP revealed a specific de-repression of the Th2 transcriptional program leading to the generation of Th2-like Treg cells that were unable to suppress extrinsic Th2 cells. Th2-like Treg cells showed increased intra-chromosomal interactions in the Th2 locus, leading to type 2 cytokine production. These findings identify a direct role for Foxp3 in suppressing Th2-like Treg cells and implicate additional pathways that could be targeted to restrain Th2 trans-differentiated Treg cells.
INTRODUCTION IPEX (immune dysregulation polyendocrinopathy enteropathy X-linked) syndrome is a recessive disease affecting exclusively males (d 'Hennezel et al., 2012) . This life-threatening disease is characterized by widespread multi-organ autoimmunity, and most of the afflicted patients die before age 3 unless treated with a bone marrow transplant. In 2001, genome linkage analysis and positional cloning identified the forkhead or winged helix family transcription factor forkhead box P3 (FOXP3) as the gene responsible for the IPEX phenotype in humans (Bennett et al., 2001; Wildin et al., 2001 ) and scurfy phenotype in mice . FOXP3 is the key transcription factor expressed predominantly in a small population of CD4 + CD25 hi T cells, termed regulatory T (Treg) cells, which are essential for maintenance of peripheral tolerance (Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 2003) . To date, there are over 75 different FOXP3 mutations described in IPEX patients (Bacchetta et al., 2018) , which cluster in the N-terminal proline-rich domain, the central leucine zipper domain, and the C-terminal forkhead (FKH) domain . While a majority of IPEX patients do not have circulating Treg cells (Gavin et al., 2006; Moes et al., 2010) , some mutations, located around the C-terminus of the protein, result in the generation of FOXP3 + CD4 + lymphocytes at frequencies similar to those found in patients expressing wild-type FOXP3 (d 'Hennezel et al., 2009; Kinnunen et al., 2013) . Nonetheless, Treg cells in these patients express reduced levels of FOXP3 and CD25 and show a severe loss of suppressive function compared to Treg cells isolated from healthy controls. These naturally occurring mutations have been invaluable in understanding the relative importance of each structural domain of FOXP3 Bin Dhuban et al., 2017; Hayatsu et al., 2017) . As a dominant suppressive population, Treg cells can inhibit the development and differentiation of T effector memory (Tem) cells and reverse autoimmunity through a diverse functional profile, including suppressive cytokine production, cell contact-dependent regulation, and metabolic control of the inflammatory environment (Lu et al., 2017) . Molecular characterization of Treg cell subsets reveal populations defined based on co-expression of transcription factors specific to Th cell lineages (T-bet: Th1, IRF4: Th2, STAT3: Th17, and BCL6 [B-cell lymphoma 6]: Tfh) (Campbell and Koch, 2011) . The co-expression of (legend continued on next page) these selective lineage-determining transcription factors generates functionally distinct subsets that can localize to distinct sites of inflammation and acquire suppressive and tissue-repair programs that effectively control ongoing tissue-specific immune responses. However, Treg plasticity and Foxp3 instability that can occur at these inflammatory sites can present a significant concern due to the loss of suppressive function and the potential acquisition of Tem functionality (DuPage and Bluestone, 2016) . To execute its functional program, Foxp3 binds to over 1,400 genes, acting as both a transcriptional repressor and an activator, depending on the promoter to which it is bound (Arvey et al., 2014; Samstein et al., 2012) . The complex regulatory function mediated by Foxp3 is achieved by its interaction with a network of other transcription factors such as RUNX1 (runtrelated transcription factor 1), NFAT (nuclear factor of activated T cells), and GATA3 (Rudra et al., 2012) . For example, GATA3 promotes Foxp3 expression and suppresses interleukin (IL) 17 cytokine production (Rudra et al., 2012; Wang et al., 2011; Wohlfert et al., 2011) . Treg-specific deletion of GATA3 results in a spontaneous inflammatory disorder in mice, highlighting its crucial role in Treg cell homeostasis and function (Rudra et al., 2012; Wang et al., 2011) . However, GATA3 is also the ''master regulator'' for Th2 cell differentiation and controls Th2 cytokine production (Yu et al., 2015) . Thus, it is essential that Foxp3 mediates a transcriptional program that allows for GATA3 expression while repressing the rest of the Th2 signature to prevent Th2-mediated immune disorders. In this regard, it has been striking that Th2 differentiation is the default developmental and trans-differentiation program in both human and mouse Treg cells after downregulation of Foxp3 (Hansmann et al., 2012; Wan and Flavell, 2007) and that many IPEX patients present with typical Th2 pathology such as atopy, eczema, eosinophilic inflammation, and hyper-IgE (hyperimmunoglobulinemia E) syndrome (Bacchetta et al., 2018) .
Bandukwala and colleagues solved a partial crystal structure of the Forkhead DNA-binding domain (FKH domain) , located at the C-terminal end of the Foxp3 protein, as part of the Foxp3: NFAT1:DNA complex (Bandukwala et al., 2011) . The structure suggested that the FKH domain supports the formation of a dimer through a domain-swap interface. The Foxp3 FKH domain is optimized to form a domain-swapped dimer due to the presence of tryptophan 348 and methionine 370 at the center of a network of hydrophobic and aromatic residues (Andersen et al., 2012; Bandukwala et al., 2011) . The large number of IPEX patients with point mutations that purported to destabilize the domain-swapped dimer of FOXP3 highlights the functional importance of this domain .
In this report, we identified a FOXP3 gene mutation in a young male patient that manifested with severe IPEX syndrome and exhibited several signs of Th2-like disease. This mutation resulted in the substitution of methionine for isoleucine at amino acid 370 (M370I) located at the core of the dimerization motif in the FKH domain of FOXP3. We hypothesized that this mutation in the domain-swap interface altered FOXP3 function and its transcriptional control of the Treg cell program, potentially causing transdifferentiation into Th2 cells. In order to perform a detailed phenotypic, biochemical, and functional analysis of this FOXP3 gene mutation, we generated a transgenic mouse that recapitulated the patient mutation. Introduction of the Foxp3 M370I gene mutation led to the formation of impaired CD4 + Foxp3 + Treg cells with a highly plastic phenotype and the acquisition of a Th2-like program, resulting in the development of a Th2-biased autoimmune disease. Molecular and functional analyses revealed chromatin remodeling at the Th2 locus with an increase in enhancer-promoter interactions, de novo binding of M370I Foxp3 to the Th2 cytokine locus, and dysregulation of the locus leading to Th2 cytokine production by the Tregs and the resulting pathogenicity.
RESULTS

Mutation M370I in the FKH Domain-Swap Interface of FOXP3 Results in IPEX Syndrome
We identified a male infant exhibiting IPEX syndrome. Shortly after birth, the patient was diagnosed with insulin-dependent diabetes mellitus and within the first month of life developed thrombocytopenia, eczematous skin rash, elevated eosinophil count, and high levels of IgE. DNA sequencing revealed a point mutation of guanine to adenine at nucleotide position 1110 in the FOXP3 gene (exon 10), resulting in substitution of methionine for isoleucine at amino acid 370 (M370I; Figures 1A and S1A ). This mutation in FOXP3 was identical to the mutation discovered in a previously identified patient . To quantify and phenotype Treg cells, we performed flow cytometry analysis on the patient's peripheral blood mononuclear cells (PBMCs). The percentage of FOXP3-expressing CD4 + Treg cells was similar to or even higher than that found in control PBMCs ( Figure 1B ; An et al., 2011) . However, mutant Treg cells exhibited increased expression of CD127 and a decreased surface expression of CD25 ( Figure 1B ). Although mutant Treg cells expressed FOXP3, the functional activity appeared to be disrupted in vivo as the patient suffered from extensive autoimmune sequelae. Ultimately, the patient required a bone marrow transplant at 4.5 months of age to replace the dysfunctional Treg cells. Figures 1C and 1D ), suggesting that thymic-derived Treg cells were generated despite this mutation within the domain-swap interface of Foxp3. However, the M370I Tg mice developed severe signs of skin and lung inflammation associated with an exacerbated Th2 immune response characterized by the presence of circulating Th2 cytokines (IL-4, IL-5, IL-13) and an overproduction of IgE without affecting total immunoglobulin G (IgG) concentration in the sera of M370I-Tg mice at 10-12 weeks of age ( Figure S2A ). The clinical symptoms of the disease required euthanizing the animals starting at approximately 20 weeks of age ( Figure 1E ). Consistent with the patient phenotype, the autoimmune manifestations were not due to the absence of Treg cells because more than 20% of CD4 + T cells that were present in PBMCs expressed Foxp3, a higher frequency than observed in wild-type mice ( Figures 1F and 1G ). We observed increased absolute numbers and percentages of M370I Treg cells in lymphoid (spleen, lymph nodes) and nonlymphoid tissues (lung, colon [large intestine lamina propria, LILP], and skin) ( Figures 1G and S2) . However, the M370I Treg cells expressed lower levels of CD25 and higher levels of CD127 ( Figure 1H ), similar to those observed in the IPEX patient, confirming the biological consequences of the M370I IPEX patient mutation. Moreover, phenotypic analysis revealed an increased number and frequency of activated CD4 + T cells (Figure 1I) suggesting severe disruption of immune homeostasis. Thus, the mouse model faithfully recapitulated aspects of the human disease and serves as an effective tool to dissect the in vivo effects of the Foxp3 mutation on Treg cell function and disease pathology.
M370I Mutation Maintains Regulatory Function of Treg Cells
The suppressive activity of M370I Treg cells was analyzed in vitro and in vivo using conventional Treg suppression assays. Treg cells isolated from lymph nodes and from the spleen were functionally suppressive in vitro, inhibiting the proliferation of naive CD4 + T cells as efficiently as the wild-type Treg cells (Figure 2A ). Figure 2E ). This proliferation was associated with a Tem phenotype characterized by increased expression of CD44 and downregulation of CD62L and CCR7 ( Figure 2E ). Programmed cell death protein-1 (PD-1) and inducible T cell co-stimulator (ICOS) were significantly upregulated in M370I Treg cells ( Figure 2F ). These two receptors have been used to identify follicular Treg cells (Tfr), so we analyzed the expression of the chemokine receptor CXCR5, one of the most common defining markers for Tfr cells (Vinuesa and Cyster, 2011) . CXCR5 surface expression was profoundly affected on M370I Treg cells isolated from the spleen and from Peyer's patches, suggesting a defect in the recruitment and function of Tfr cells in the M370I Tg mice ( Figure 2G ). In summary, the M370I mutation resulted in the induction of a highly proliferative population of effector-memory Treg cells expressing immunoregulatory molecules similar to those seen on wild-type Treg cells. Nonetheless, the M370I mutation altered the ability of Treg cells to maintain immune homeostasis.
The M370I Foxp3 Mutation Drives the Differentiation of Th2 Treg Cells
To analyze the molecular changes associated with the M370I mutation, we performed RNA sequencing (RNA-seq) on Treg cells isolated from secondary lymphoid organs of 3-week-old asymptomatic wild-type and M370I Tg mice. Among the top upregulated genes (>5-fold change and adjusted p value < 0.05), we noted that Th2 cytokines such as Il4, Il5, and Il13 were highly expressed in M370I Treg cells compared to their expression in wild-type Treg cells ( Figure 3A ). Expression of Th2 cytokines was validated by qRT-PCR ( Figure 3B ), ELISA ( Figure 3C ), and intracellular flow cytometry ( Figure 3D ). This Th2 transcriptional program was associated with an upregulation of the Th2 master transcription factor GATA3 in M370I Treg cells. Up to 50% of M370I Foxp3 + cells co-expressed ICOS and GATA3 compared to only 10%-20% of wild-type Treg cells isolated from lymph nodes ( Figure 3E ). The a-chain of the cytokine receptor IL-33R (St2 (legend continued on next page) or IL1RL1, interleukin 1 receptor-like 1) and the differentiation marker KLRG1, which are associated with GATA3 expression in Treg cell and Th2 cells (Delacher et al., 2017) , were not upregulated in the M370I Treg cells compared to those in wild-type Tregs ( Figure 3F ). M370I Treg cells also expressed high levels of CD85k, also known as ILT3 (immunoglobulin-like transcript 3) ( Figure 3G ), a receptor discovered on a Treg subpopulation that promotes Th2 immune responses in vitro and in vivo by inducing the maturation of IRF4 + PD-L2 + dendritic cells (DCs) (Harakal et al., 2016; Ulges et al., 2015) . Indeed, the M370I Tg mice presented an increased frequency of Th2-promoting IRF4 + PD-L2 + cells among the CD11c + MHCII + splenic DCs ( Figure 3G ).
Finally, mutant Treg cells exhibited increased expression of PD-1 ( Figure 2E ), which has previously been shown to impair the ability of Treg cells to suppress Th2 cell differentiation (Yang et al., 2017) . Taken together, these results suggest that M370I Treg cells could promote Th2 immune responses through multiple mechanisms: the production of Th2 cytokine; the expression of CD85k; and finally, the upregulation of PD-1, which hinders the ability to control Th2 effector cells. Figure 4C, bottom panel) . These results indicate that the dysregulated Th2 program, including Th2 cytokine production by mutant Treg cells, was a cell-intrinsic effect driven by M370I Foxp3 independent of an IL-4 feedback loop generated by the autoimmune disease. We also adopted a genetic strategy to confirm the key role of the M370I Foxp3 mutation in the generation of the Th2-like phenotype in mutant Treg cells. T cell-specific IL-4-and IL-13-deficient mice were crossed with the M370I mutant animal. In the absence of IL-4 and IL-13 production by T cells, we observed an increased percentage of ICOS + GATA3 + and increased expression of CD85k ( Figure 4D) on mutant Treg cells, although Th2 cytokine signaling was important for maximal GATA3 expression ( Figure 4D ). Together, these results confirm the critical role of IL-4 signaling in the activation and maintenance of GATA3 expression in CD4 + T cells. The data also substantiate the intrinsic role of the M370I mutation in the generation of Th2-cell-like Treg cells, characterized by the expression of GATA3 and the secretion of the canonical Th2 effector cytokines. Overall, these data demonstrate that Treg cell dysregulation induced by the IPEX mutation is due to a cell-intrinsic Treg defect driven by M370I Foxp3 independent of IL-4 and IL-13 produced by T effector cells. Nonetheless, maximal expression of GATA3 in M370I Treg and presumably in Th2 effector cells is controlled by a feed-forward loop that stabilizes and/or enhances the Th2-cell-like phenotype of the mutant Treg cells.
M370I Mutation Leads to Increased Enhancer-Promoter Interaction at a Limited Number of Loci
Foxp3 acts mainly as a repressor of gene transcription by binding to distal enhancers (Arvey et al., 2014) . Thus, we examined the enhancer-promoter (E-P) looping interactions as a readout for molecular consequences of the M370I Foxp3 mutation and its effects on gene expression. In a recent paper, Mumbach et al. (2017) showed that immunoprecipitation for histone modification H3K27ac, which correlates with active enhancers and promoters, could be coupled with a ligation reaction in HiChIP to identify E-P chromatin interactions across the genome in primary cells (Mumbach et al., 2017) . We performed H3K27ac-HiChIP analysis to create high-resolution contact maps of active enhancers in wild-type and M370I Treg cells ( Figure S4 ). ) and CD85k expressing Treg cells (lower panel) present in the spleens from 3-week-old wild-type M370I mice or M370 T cell-specific Il4-Il13 deficient mice. Data are representative of three independent experiments with n = 3. All the cells were sorted as described in STAR Methods from wild-type and M370I littermates at 3-4 weeks of age, unless otherwise stated. See also Figure S3 .
Comparison of the H3K27ac loops between Foxp3 wild-type and Foxp3-M370I cells revealed a limited number of significant changes. Of a total of 9,895 loops, only 281 loops (2.8%) were differentially identified between wild-type and M370I samples ( Figure 5A ; Tables S1 and S2). 50% of these loops showed an increased chromatin interaction in the M370I mutant cells (Figure 5A) . These M370I-biased loops were shown to be Treg specific because only 5% of the loops overlapped with loops enriched in the effector T cells isolated from the same Tg mice (Table S2 , loops highlighted in red). The Treg-specific chromatin loops were compared to Foxp3 ChIP-seq data (Arvey et al., 2014; Samstein et al., 2012) to identify the loops with Foxp3-binding sites. Of the Foxp3 mutant-biased loops, 26.62% contained Foxp3 ChIP peaks at their anchors (Table S2 , loops highlighted in green), whereas only 6.34% of wild-type-biased loops had Foxp3 ChIP peaks (Table S2 , loops highlighted in green). This is consistent with a predominant role of Foxp3 as a repressor and suggests that the M370I mutation affects Foxp3 suppressive function and its capacity to inhibit E-P interactions by altering the chromatin architecture (3D interactions) of Foxp3 target genes. Gata3 gene was among the most enriched M370I Foxp3 mutant-biased loops, showing a significant increase in E-P interactions ( Figures 5A and 5B ). This upregulation of specific peaks in the H3K27ac HiChIP signal was due to a direct loss of repressive activity by M370I Foxp3 rather than the mutation impairing DNA binding of Foxp3. Indeed, analysis of genome-wide Foxp3 DNA-binding sites in both wild-type and M370I Treg cells by using chromatin immunoprecipitation followed by high-throughput DNA sequencing (ChIP-seq) revealed an overall increased DNA binding of the M370I Foxp3 ( Figure 5C ). Over 2,372 unique peaks were identified by Foxp3 ChIP-seq (Table S3) , and the majority (70%) were shared between wild-type and M370I Foxp3 cells. 4% were enriched in the wild-type sample and 25% of peaks were enriched in the M370I samples ( Figure 5C ). Thus, the M370I mutation did not abrogate Foxp3 binding to DNA. To validate the robustness of our Foxp3 ChIP-seq, we compared our dataset with previously published ChIP-seq data using the same anti-Foxp3 antibody (Samstein et al., 2012) . There was a strong correlation between the two wild-type ChIP-seq datasets (Pearson correlation coefficient = 0.87) at the genome-wide level, suggesting good reproducibility. In addition, analysis of Cd28, Ctla4, and IL2ra, three well-defined Foxp3 target genes, demonstrated unchanged chromatin architecture and a similar binding pattern of Foxp3 between all the samples (Figures 5D and S5 ). In addition, a similar or even higher Foxp3 ChIP signal for the M370I mutant protein was observed when focusing on the E-P loops with highest H3K27ac HiChIP signals ( Figure 5E ). The deregulation of Gata3 was associated with increased looping at multiple Th2 signature genes such as Maf, Tnfsf8, Il10, and Il4, suggesting a selective loss of repressive activity for a subset of genes controlling Th2 effector function (Figures 5A and S5) . In summary, the M370I mutation inhibited the repressive function of Foxp3 and led to increased interactions between enhancers and promoters at a small number of key genes involved in Th2 effector function. These results support that there is a cell-intrinsic defect of M370I Foxp3 in mutant Treg cells that leads to changes in Gata3 and other Th2-related gene expression and to the development of dysfunctional Treg cells.
M370I Mutation Leads to Binding of Foxp3 to the Th2 Locus
Integration of genome-wide RNA-seq, Foxp3 ChIP-seq, and H3K27ac HiChIP from M370I mutant Treg cells enabled the identification of Foxp3 target gene(s) that may contribute to the disease-associated phenotype. We focused on genes marked by H3K27ac loops that were bound by mutant M370I Foxp3. Indeed, the majority of the Foxp3-specific loops had increased E-P interactions with M370I mutation (Table S2 , loops highlighted in green). In total, 698 genes were upregulated, 610 Foxp3-ChIP peaks were enriched, and 139 H3K27ac HiChIP loops were identified in M370I mutant Treg cells. When combined in a Venn diagram ( Figure 6A ), only 7 genes were identified in all three datasets. Among these 7 genes, 5 were associated with Th2 immune responses (Cxcr6, Il4, Il10, Mapre2, and Tnfsf8). Although the majority of these genes are known to be Foxp3 target genes, the Il4 gene had not previously been identified as a Foxp3 target. Detailed analysis of the Th2 locus, which included Il4, Il5, Il13, Rad50, and Kif3a, revealed enriched binding of M370I Foxp3 to multiple sites along this locus, which encodes for Th2 cytokines ( Figure 6B ). These binding sites were unique to M370I mutant Foxp3 because no statistically significant bindings were identified in wild-type samples or in the published Foxp3 ChIP-seq datasets ( Figure 6B ; Samstein et al., 2012; Kitagawa et al., 2017) . Taken together, in-depth genomic analysis of mutant Treg cells identified de novo Foxp3 binding sites in the Th2 locus, which were dependent on the Foxp3 M370I mutation.
M370I Mutation Leads to Deregulation of the Th2 Locus
It is well established that the coordinated expression of Th2 cytokines is controlled by chromatin conformation at the locus encoding these genes (Lee, 2014) . This spatial organization is generated by cis-regulatory elements and specific transcription factors that mediate the formation of long-range chromosomal interactions (Spilianakis and Flavell, 2004) . Alignment of the Foxp3 ChIP peaks revealed that the M370I mutant Foxp3 binding sites were localized to cis-acting conserved noncoding sequence 2 (CNS2) regulatory elements, DNase-I-hypersensitive site 2 (HS2, the Il4 intronic enhancer), CGRE (Il13 distal promoter), and Rad50 DNase-I-hypersensitive sites RHS6 and RHS7 ( Figures 6B and  6C) . Interestingly, M370I mutant Foxp3 bound the Th2 locus control region (LCR), which controls the expression of all three Th2 cytokines and mediates intra-chromosomal interactions (Lee et al., 2003) . In order to determine if the binding of M370I mutant Foxp3 affects the Th2 locus conformation, high-resolution contact maps were generated from the H3K27ac HiChIP data using the Il4 promoter as the anchor point (dotted line, Figure 6C ). The analysis enabled the visualization of virtual 4C plots for the Th2 locus ( Figure 6C ) and demonstrated a greater intra-chromosomal interaction in M370I Foxp3 mutant Treg cells. This pattern of DNA interaction between Il4 and the cis-regulatory element is unique to the mutant Treg cells because there were no similar loops observed in the wild-type Treg cells. These long-range chromosomal interactions are mediated by transcription factors, such as GATA3 (Spilianakis and Flavell, 2004) and special AT-rich sequence-binding protein-1 (SATB1) (Cai et al., 2006) . As predicted by the spatial reorganization of the Th2 locus, coordinated upregulation of GATA3 and SATB1 was observed by flow cytometry in M370I Foxp3
+ activated Treg cells ( Figure 6D ). GATA3 and Foxp3 have been shown to cooperate and occupy the same Figure S5 and Tables S1, S2 , and S3. HiChIP. Pooling these three complementary approaches has generated a list of seven genes. ), whereas GATA3 did not interact strongly with the Th2 locus in transforming growth factor beta (TGF-b)-induced Treg cells (iTregs) (Wei et al., 2011) . This observation was consistent with experiments revealing that Th2 cytokines were not produced by iTreg cells expressing the mutant Foxp3 ( Figure 6F ), suggesting that M370I Foxp3 and GATA3 have to bind the Th2 cis-acting regulatory elements together to induce expression of Il4, Il5, and Il13 in Treg cells. To determine the molecular cooperation between GATA3 and M370I Foxp3, CRISPRCas9 gene editing system was used to knock out Gata3 in Treg cells from wild-type and M370I mutant mice. Rosa26
Cas9 mice were crossed with the M370I mutant mice and a retroviral approach was used to introduce the sgRNA targeting Gata3.
The majority (>80%) of the cells infected with the virus expressing
Gata3-specific sgRNAs down-regulated GATA3 protein expression ( Figure 7A ). In the absence of GATA3, Th2 cytokine production by M370I Treg cells was reduced ( Figures 7B and 7C) , and the percentage of Treg cells producing cytokines was reduced to the level of the wild-type Treg cells ( Figure 7C ). These observations demonstrate a unique cooperation between M370I Foxp3 and GATA3, which led to the coordinated production of the canonical Th2 effector cytokines and drives a Th2-like phenotype in Treg cells.
DISCUSSION
Naturally occurring IPEX mutations provide unique insight into FOXP3 biology, which can be utilized to identify new pathways regulating Treg cell homeostasis and function (Bin Dhuban et al., 2017; Hayatsu et al., 2017) . In this study, we identified an IPEX patient with an M370I mutation in FOXP3 who developed a number of autoimmune manifestations, including several pathologies consistent with Th2 cell-mediated disease. We generated a transgenic mouse model in which the wild-type Foxp3 gene was disrupted and replaced with a mutant allele of Foxp3 that mimicked the mutation identified in the patient. This mutation led to the development of a disease similar to the one observed in the IPEX patient, namely, a Th2-like autoimmune syndrome.
A paradigm in T cell biology is the existence of different effector T cell subsets (Th1, Th2, Th17, and Tfh) defined by the expression of master transcription factors, T-bet, GATA3, RORgt (Retinoic-acid-receptor-related orphan nuclear receptor gamma), and Bcl-6, respectively (Campbell and Koch, 2011) . These key transcription factors are induced during the initiation of the immune response and control T cell differentiation, function, and migration. Moreover, activated Treg cells can co-opt these transcriptional programs to tailor their phenotypic and functional characteristics to those of the CD4 + effector T cells Rivas et al., 2015; Reubsaet et al., 2013) , in tumor environments (Halim et al., 2017) , and in the context of IL-2 therapy (Birjandi et al., 2016) (Hayatsu et al., 2017) . A384T mutant Treg cells produce Th2 cytokines, and our analysis of the Foxp3 ChIP-seq dataset from the Hayatsu study revealed that A384T mutant Foxp3 also bound to the Th2 locus. These combined observations strongly suggest a role of Foxp3 in controlling Th2 programming in Treg cells. Because neonatal immunity shows an inherent polarization of CD4 + T cells toward Th2 immunity (Restori et al., 2018) and because the Th2 arm of the immune response is the most sensitive to Treg dysfunction (Tian et al., 2011) , it was crucial to separate a direct effect of M370I Foxp3 driving the Th2 transcriptional program in the mutant Treg cells from a secondary effect due to an indirect response to a dominant Th2 environment. The systemic inhibition of IL-4 by neutralizing antibodies or the T cellspecific genetic ablation of Il4 and Il13 provided evidence for a direct effect of mutant Foxp3 on the Th2-like Treg phenotype. In addition, the expression of IL4ra by Treg cells enables a feed-forward loop to drive and stabilize the Th2-cell-like phenotype by maintaining optimal GATA3 expression (Noval Rivas et al., 2015) and amplifying Th2 reprogramming by both Foxp3 mutant-dependent and independent mechanisms. In conclusion, IPEX mutations provide unique opportunities to leverage clinical observations to increase our understanding of fundamental Treg biology. Analysis of Foxp3 mutation M370I showed a direct role of a mutant Foxp3 protein in the Th2-like phenotype observed during Treg dysfunction and revealed the complex interplay between the regulatory function of Foxp3 and the Th2 effector program. A better understanding of the mechanisms controlling the differentiation of Th2-like Treg cells will inform novel therapeutic strategies for diseases like allergies, asthma, and cancer.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Samples PBMCs were collected from 4-month-old male patient diagnosed with IPEX mutation M370I and from a healthy 7-year-old male child. Cells were freshly isolated and evaluated for expression of CD4, CD25, CD127 and FOXP3. Intracellular staining was performed with FOXP3 staining kit according to the manufacturer's instructions (BioLegend). Informed written consents were obtained in accordance with the reviewed and approved policies and procedures at the University of California, San Francisco (UCSF). Ethics approval was granted by the UCSF Institutional Review Board.
Mouse Models
The single nucleotide variant c.1110G>A identified in IPEX patients was inserted via standard recombineering (Lee et al., 2001) were used for flow cytometry analysis with the indicated antibodies. Cells were stain with a fixable live/dead stain (Invitrogen) and fixed with BD Cytofix/Cytoperm (BD Biosciences) for cytokines detection or eBioscience Foxp3 staining buffer set (ThermoFisher). Flow cytometry was performed on LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo software and compiled using Prism.
Retroviral Production
The sgRNA against mouse gata3 (TTCCGTAGTAGGACGGGACG) was design with the sgRNA designing software at Benchling (https://benchling.com) and cloned under a U6 promoter into MSCV-IRES-Thy1.1. Retroviral Plat-E packaging cells were transfected with the indicated plasmids using Fugene and the retroviral supernatant was used fresh.
In vitro Expansion Treg Cells and Retroviral Transduction
Sorted Treg cells were stimulated with anti-CD3 and anti-CD28 Dynabeads at a 1:3 cell:bead ratio, supplemented with 2,000 IU/ml rhIL-2 (Chiron Corp) in complete medium. The cultures were monitored daily and maintained at 0.7-1 3 10 6 cells/ml by diluting with IL-2-supplemented complete medium. Twenty-four hours after activation, Treg cells were centrifuged (90 minutes, 6000 rcf at 25 C) with viral supernatant supplemented with 10 mg/ml polybrene and after 3 or 4 days cells were harvested, rested overnight (anti-CD3 and anti-CD28 beads were removed with magnetic rack) and stimulated with 0.5 mM ionomycin, 10 ng/ml phorbol myristate acetate (PMA) and 3 mg/ml of Brefeldin A at 37 C for 3-4 hours before being fixed and permeabilized (Cytofix/Cytoperm) and stained for intracellular proteins.
Cytokine Production Lymphocyte cells were activated at 10310 6 cells/ml with 0.5 mM ionomycin, 10 ng/ml PMA and 3 mg/ml of Brefeldin A at 37 C for 3-4 hour before labeling with LIVE/DEAD fixable dead stain, and staining for CD4, CD8, Foxp3, IL-10, IL-4, IL-5 and IL-13 using Cytofix/Cytoperm.
In vivo IL-4 Neutralization 2 weeks old M370I mutant mice were treated every other day for one week with 0.5mg of IL-4 neutralizing antibody (11B11) or rat IgG1 isotype control. Spleens were collected at 3 weeks of age and CD4 + T cells were analyzed for IL-4 and IL-13 cytokines production after PMA-ionomycin activation.
In Vitro Stimulation and Suppression Assays Graded numbers of fresh sorted Treg cells were added to 50,000 CD4 + T cells stimulated with 50,000 irradiated splenic APC (spleen of Rag1 À/À mice, red blood cell lysis and g-irradiation (2,000 rad)) and 1 mg/ml anti-CD3 (clone 145-2C11) in a U-bottomed 96-well plate. Responder CD4 + T cells were labeled with Cell Trace Violet (CTV) before the assay, and the level of proliferation was assessed by determining the dilution of CTV using flow cytometry 72-96 h after the initiation of the culture. Alternatively, Treg cells were co-cultured with CTV labeled responder CD4 + T cells in an APC free system in the presence of plate bound anti-CD3 (clone 145-2C11) and anti-CD28 (clone PV-1) mAbs (0.5 mg/ml each). After 4 days cells were harvested and labeled with LIVE/DEAD fixable dead stain before being fixed and permeabilized (Foxp3 Staining Kit, Thermo Fisher Scientific) for intracellular staining.
iTreg Induction Naive CD44 low CD62L
hi CD25 -CD4 + T cells were sorted from pooled LN and spleen, activated with plate bound anti-CD3 (clone 145-2C11) and anti-CD28 (clone PV-1) mAbs (0.5 mg/ml each) with 100U/ml of recombinant human IL-2 (Proleukin) and 20 ng/ml human recombinant TGF-b (Humanzyme). After 3 or 4 days cells were harvested, rest overnight and stimulated with 0.5 mM ionomycin, 10 ng/ml PMA and 3 mg/ml of Brefeldin A at 37 C for 3-4 hours before being fixed and permeabilized (Cytofix/Cytoperm) and stained for intracellular proteins.
Cytokine and Ig ELISA Cytokine concentrations were measured by commercial ELISA kits according to the manufacturer's recommendations (Thermo Fisher Scientific) 
DATA AND SOFTWARE AVAILABILITY
The GEO accession number for the RNA-seq, Foxp3 CIP-seq, and H3K27ac HiChIP data reported in this paper is GSE112176.
